Formulation and preclinical assessment of a dual - drug transdermal delivery system for alzheimer’s disease management
Future Journal of Pharmaceuticals and Health Sciences · 11.10.2025 · 5 (2) · 86-95
DOI: 10.26452/fjphs.v5i2.550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Journal of Pharmaceuticals and Health Sciences, online erschienen am 11.10.2025. Verfasst von {"name":"Bariki Rajasekhar","email":"sekhar92raj@gmail.com","affiliation":"R und 1 weiteren Autor:innen.
Themen: Demenz
Abstract (Originalsprache)
The present investigation aimed to design and evaluate a dual - drug transdermal therapeutic system for the concurrent delivery of Donepezil and Memantine, intended to improve therapeutic outcomes in the management of Alzheimer’s disease. Transdermal matrix patches were prepared by the solvent casting method employing a combination of hydroxypropyl methylcellulose, modified chitosan, and polyethylene glycol as film - forming polymers. A Quality by Design approach using Box – Behnken experimental design was applie d to optimize formulation parameters and to understand the influence of critical variables on drug release and mechanical properties. The prepared systems were characterized for physicochemical attributes such as thickness, folding endurance, surface pH, a nd drug content uniformity. In vitro release and ex vivo permeation studies were conducted to assess drug diffusion behavior, followed by in vivo pharmacokinetic evaluation. The optimized formulation exhibited satisfactory mechanical strength, uniform drug distribution, and acceptable flexibility. Drug release studies demonstrated a sustained release pattern for both active agents over an extended period. Permeation studies confirmed effective transdermal transport across the biological membrane. Pharmacoki netic analysis indicated prolonged plasma drug levels with improved bioavailability when compared to conventional oral formulations. The developed dual - drug transdermal system provides a promising alternative to oral therapy for Alzheimer’s disease by enab ling controlled drug delivery, reducing systemic fluctuations, and enhancing patient compliance. This approach may offer improved long - term management of the disease.
Zitieren
APA
Rajasekhar","email":"sekhar92raj@gmail.com","affiliation":"R, N., & Chinthaginjala","email":"sekhar92raj@gmail.com","affiliation, N. (2025). Formulation and preclinical assessment of a dual - drug transdermal delivery system for alzheimer’s disease management. Future Journal of Pharmaceuticals and Health Sciences, 5(2), 86-95. https://doi.org/10.26452/fjphs.v5i2.550
Vancouver
Rajasekhar","email":"sekhar92raj@gmail.com","affiliation":"R N, Chinthaginjala","email":"sekhar92raj@gmail.com","affiliation N. Formulation and preclinical assessment of a dual - drug transdermal delivery system for alzheimer’s disease management. Future Journal of Pharmaceuticals and Health Sciences. 2025;5(2):86-95. doi:10.26452/fjphs.v5i2.550
BibTeX
@article{RajasekharemailsekharrajgmailcomaffiliationR2025,
author = {Rajasekhar","email":"sekhar92raj@gmail.com","affiliation":"R, "name":"Bariki and Chinthaginjala","email":"sekhar92raj@gmail.com","affiliation, "name":"Haranath},
title = {Formulation and preclinical assessment of a dual - drug transdermal delivery system for alzheimer’s disease management},
journal = {Future Journal of Pharmaceuticals and Health Sciences},
year = {2025},
volume = {5},
number = {2},
pages = {86--95},
doi = {10.26452/fjphs.v5i2.550}
}
EUVIMED